This study is for patients with Type 2 Diabetes currently taking Ozempic, Trulicity, or Victoza. Instead of taking these meds, participants will switch to Tirzepatide (Mounjaro) for 3 months. Mounjaro is a once-weekly injection recently approved by the FDA for Type 2 Diabetes and has been shown to cause weight loss. The purpose of the study is to compare changes in A1C.
All participants enrolled in this study will receive Mounjaro at no charge and will be compensated for their time and travel.
Participant Eligibility Criteria ( To take part in the study )